de.mpg.escidoc.pubman.appbase.FacesBean
Deutsch
 
Hilfe Wegweiser Datenschutzhinweis Impressum Kontakt
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Zeitschriftenartikel

Design, Synthesis, and Biological Evaluation of Quercetagetin Analogues as JNK1 Inhibitors

MPG-Autoren
http://pubman.mpdl.mpg.de/cone/persons/resource/persons77697

Baek,  Sohee
Huber, Robert / Structure Research, Max Planck Institute of Biochemistry, Max Planck Society;

http://pubman.mpdl.mpg.de/cone/persons/resource/persons84628

Arciniega,  Marcelino
Huber, Robert / Structure Research, Max Planck Institute of Biochemistry, Max Planck Society;

http://pubman.mpdl.mpg.de/cone/persons/resource/persons78142

Huber,  Robert
Huber, Robert / Structure Research, Max Planck Institute of Biochemistry, Max Planck Society;

Externe Ressourcen
Es sind keine Externen Ressourcen verfügbar
Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Hierold, J., Baek, S., Rieger, R., Lim, T.-G., Zakpur, S., Arciniega, M., et al. (2015). Design, Synthesis, and Biological Evaluation of Quercetagetin Analogues as JNK1 Inhibitors. CHEMISTRY-A EUROPEAN JOURNAL, 21(47), 16887-16894. doi:10.1002/chem.201502475.


Zitierlink: http://hdl.handle.net/11858/00-001M-0000-0029-596E-D
Zusammenfassung
The recent discovery of c-Jun NH2-terminal kinase JNK1 suppression by natural quercetagetin (1) is a promising lead for the development of novel anticancer agents. Using both X-ray structure and docking analyses we predicted that 5'-hydroxy-(2) and 5'-hydroxymethyl-quercetagetin (3) would inhibit JNK1 more actively than the parent compound 1. Notably, our drug design was based on the active enzyme-ligand complex as opposed to the enzyme's relatively open apo structure. In this paper we test our theoretical predictions, aided by docking-model experiments, and report the first synthesis and biological evaluation of quercetagetin analogues 2 and 3. As calculated, both compounds strongly suppress JNK1 activity. The IC50 values were determined to be 3.4 mu M and 12.2 mu M, respectively, which shows that 2 surpasses the potency of the parent compound 1 (IC50=4.6 mu M). Compound 2 was also shown to suppress matrix metalloproteinase-1 expression with high specificity after UV irradiation.